- Conditions
- Hepatitis C Infection, HIV Infection
- Interventions
- Nitazoxanide With Pegylated Interferon And Ribavirin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–126
of 126
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
- Drug · Other
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
- Conditions
- Chronic Hepatitis C
- Interventions
- SCV-07
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Anaheim, California • Louisville, Kentucky • Cincinnati, Ohio + 1 more
- Conditions
- Hepatitis C
- Interventions
- BI 201335, PegIFN/RBV
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more
- Conditions
- Hepatitis C
- Interventions
- Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV)
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Miravirsen, Telaprevir, Ribavirin
- Drug
- Lead sponsor
- Santaris Pharma A/S
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas